In summary, this study elucidates the significance of BCAT1-mediated BCAA metabolic reprogramming in enhancing cell survival and TKI resistance in NSCLC, which provided extensive evidence for directly targeting BCAT1 as a therapeutic strategy for lung cancer. This evidence concerns the gene BCAT1 and non-small cell lung carcinoma.